Sources Sought Notice to Identify Potentially Capable, Interested Parties for Biospecimen Collection and Biobanking Services
Department of Health and Human Services · National Institutes of Health
Description
TYPE OF NOTICE: This is a Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The National Institutes of Health (NIH) Office of Acquisitions and Logistics Management, on behalf of the National Cancer Institute’s (NCI’s) Division of Cancer Treatment and Diagnosis (DCTD), is issuing this Sources Sought Notice to conduct market research and identify interested and capable parties, including both large and small businesses, that have the resources and expertise to support biospecimen collection, biobanking, and related services. The required services will support cancer research across the United States by providing specialized expertise to identify, establish, and manage clinical sites across the nation to engage and enroll cancer patients onto NCI biospecimen collection protocols, collect biospecimens and associated medical data, and to provide biorepository services. Research studies may include, but are not limited to, development of patient-derived animal models, tumor characterization, pharmacokinetic and pharmacodynamic studies, assay development and validation, clinical testing, and collection and management of biospecimens for future use. The Government intends to procure these specialized services through a competitive acquisition. BASED ON THE RESPONSES TO THIS SOURCES SOUGHT NOTICE (MARKET RESEARCH), all Small Business Set-Aside categories will be considered for this procurement. Telephone inquiries will not be accepted or acknowledged, and no feedback or evaluations will be provided to companies regarding their submissions. PLACE OF PERFORMANCE: Performance of services for this effort will primarily take place at Contractor and/or Subcontractor facilities. DISCLAIMER:THIS SOURCES SOUGHT IS FOR INFORMATIONAL PURPOSES ONLY. THIS IS NOT A “REQUEST FOR PROPOSAL (RFP)”. IT DOES NOT CONSTITUTE A SOLICITATION AND SHALL NOT BE CONSTRUED AS A COMMITMENT BY THE GOVERNMENT. RESPONSES IN ANY FORM ARE NOT OFFERS AND THE GOVERNMENT IS UNDER NO OBLIGATION TO AWARD A CONTRACT AS A RESULT OF THIS ANNOUNCEMENT. NO FUNDS ARE AVAILABLE TO PAY FOR PREPARATION OF RESPONSES TO THIS ANNOUNCEMENT. ANY INFORMATION SUBMITTED BY RESPONDENTS TO THIS NOTICE IS STRICTLY VOLUNTARY. RESPONSES WILL NOT BE RETURNED TO THE RESPONDER. NOT RESPONDING TO THIS NOTICE DOES NOT PRECLUDE PARTICIPATION IN ANY FUTURE REQUEST FOR QUOTE (RFQ), INVITATION FOR BID (IFB) OR RFP, IF ISSUED. IF A SOLICITATION IS RELEASED, IT WILL BE SYNOPSIZED ON THE GOVERNMENT-WIDE POINT OF ENTRY (GPE). IT IS THE RESPONSIBILITY OF POTENTIAL OFFERORS TO MONITOR THE GPE FOR ADDITIONAL INFORMATION PERTAINING TO THIS REQUIREMENT. THE GOVERNMENT RESERVES THE RIGHT TO USE INFORMATION PROVIDED BY RESPONDENTS FOR ANY PURPOSE DEEMED NECESSARY AND LEGALLY APPROPRIATE. ANY ORGANIZATION RESPONDING TO THIS NOTICE SHOULD ENSURE THAT ITS RESPONSE IS COMPLETE AND SUFFICIENTLY DETAILED TO ALLOW THE GOVERNMENT TO DETERMINE THE ORGANIZATION'S QUALIFICATIONS TO PERFORM THE WORK. PROGRAM BACKGROUND: NCI uses research biospecimens including tissues, blood, and other bodily fluids donated by patients as part of scientific research to develop novel diagnostics and therapies for cancer. The Contractor shall be responsible for providing services to identify and engage clinical sites in conducting NCI biospecimen collection studies and to provide biorepository services for concurrent multi-disciplinary studies and diverse study designs. Biospecimens and associated data of known quality are a critical resource for research that investigates the causes, biology, diagnosis, prevention, and treatment of cancer. NCI requires biospecimens for research purposes that may include, but are not limited to, the following: development of patient-derived models, characterization of tumors using clinical- and research-grade sequencing, proteomics studies, pharmacodynamic studies, development and validation of clinical assays, performance of clinical testing and return of clinical test results to providers and patients, and development of research reserves of biospecimens for future research use. REQUIRED CAPABILITIES: The objective of any potential contract is to obtain specialized services for the identification and coordination of clinical sites in the management of specific NCI biospecimen collection studies and the collection, processing, storage, and distribution of biospecimens and associated data for current and future cancer research. For specific details under each domain, please reference the draft Statement of Work which accompanies announcement. The Government encourages feedback from respondents in their capability submissions (i.e., comments, suggestions, recommendations) on the draft Statement of Work that would improve the understanding of the requirements for this anticipated acquisition. NCI is seeking the following information from respondents regarding strategies as well as explicit examples of how they would propose to support NCI initiatives in one or more of the following services areas: DOMAIN 1: CLINICAL SITE IDENTIFICATION AND ONBOARDING, CLINICAL SITE MANAGEMENT, TRAINING, PROVISION OF KITS, AND IDENTIFICATION OF EXISTING BIOSPECIMEN COLLECTIONS Domain 1 describes the biospecimen collection activities needed to identify and manage medical institutions (herein referred to as Clinical Sites) across the United States and Canada to engage and enroll cancer patients onto specific NCI biospecimen collection studies and to provide biospecimen collection kit services for the studies. NCI biospecimen collection studies will include collection of biospecimens and associated medical data. Some studies will require the identification of existing cancer biospecimen collections that meet quality and quantity metrics prescribed by the NCI and that are appropriately consented for use by NCI. The Contractor shall ensure these activities are conducted safely, efficiently, and in compliance with regulatory requirements as specified
Truncated. Read the full description and attachments on SAM.gov.